Clinical Trial

Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI

Study acronym: FLORENCE

Recruiting

Record status

This record was last updated November 17, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Summary

All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion. The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available. The primary objective of the study is the effect of short-term and long-term SGLT2i therapy on the occurrence of CI-AKI in patients undergoing diagnostic or therapeutic procedures with ICM.

Trial Details

NCT Number	NCT07231939
Lead Sponsor	Collegium Medicum w Bydgoszczy
Conditions	Coronary Artery Disease, Acute Kidney Injury, Contrast-Induced Acute Kidney Injury, Percutaneous Coronary Intervention
Enrollment	4,000 participants
Start Date	2025-11-01
Primary Completion	2025-12-31 (estimated)
Study Completion	2026-03-31 (estimated)
Updated on ClinicalTrials.gov	2025-11-17